HTA - - Health Technology Assessment Report

eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis (Structured abstract)

Code: HTA-32014000310 **Year:** 2012 **Date:** 2012

Author: Pichon Riviere A

Study design (if review, criteria of inclusion for studies)

HTA report

Interventions

eFlow® vibrating membrane nebulizer

Outcome measures

The information included in this report comes from small, low methodological quality studies and most of them do not report relevant clinical results. The only advantage shown in the published studies is shorter nebulization time with eFlow® when compared with conventional devices. However, this does not show relevant clinical benefits beyond its potential better adherence. Also, one study mentions that its performance may decrease after 6 months in use. In addition, there are other nebulizers (e.g., I-neb®) with which it may be compared, since they have potential advantages. So far, based on the evidence found, there is no evidence that shows the clinical benefit of eFlow® over conventional devices beyond nebulization times. More properly designed studies are required to assess if eFlow® would have a relevant benefit in patients with cystic fibrosis.

http://www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=1291& amp;origen_publicacion=publicacione

See also

Health Technology Assessment Database - Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A. eFlow® (nebulizador de membrana vibrante) para el tratamiento de la fibrosis quística. [eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°255. 2012

Keywords

Anti-Bacterial Agents; Bacterial Infections; Infection; Inhalation OR nebulised; pharmacological_intervention; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; non pharmacological intervention - devices OR physiotherapy;